1352422-08-2

Upstream product

• 16013-85-7 2,6-dicholoro-3-nitropyridine 
• 1276676-86-8 5-chloro-1-(2,2-dimethylpropyl)-3-methyl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one 
• 89660-20-8 5-chloro-3-methyl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one 
• 89660-14-0 6-chloro-N²-methylpyridine-2,3-diamine 
• 33742-70-0 6-chloro-N-methyl-3-nitropyridin-2-amine 

Relevant academic research and scientific papers

Discovery of 5-aryl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-ones as positive allosteric modulators of metabotropic glutamate subtype-2 (mGlu2) receptors with efficacy in a preclinical model of psychosis

Optimization of a benzimidazolone template for potency and physical properties revealed 5-aryl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-ones as a key template on which to develop a new series of mGlu2 positive allosteric modulators (PAMs). Systematic invest

POSITIVE ALLOSTERIC MODULATORS OF MGLUR2

The present invention is directed to 5-substituted 1,3-dihydro-2H-imidazo[4,5-b]pyridine-2-one derivatives which are positive allosteric modulators of the mGluR2 receptor, useful in the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGluR2 receptor is involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which metabotropic glutamate receptors are involved, such as schizophrenia.